Figure 5.

In vitro effects of combining BsAb5003 with several MM treatment drugs. OPM-2 cells were co-cultured with hPBMCs with (blue bar) or without (red bar) 5 pM of BsAb5003 in combination with (a) lenalidomide, (b) pomalidomide, (c) bortezomib, or (d) carfilzomib. On the first day of incubation, culture supernatants were collected for cytokine measurement using the Luminex system. After 3 days of incubation, cells were collected for cytotoxicity, CD4 + T cell and CD8 + T cell activation measurements by flow cytometry. The assay was conducted in triplicate or duplicate and the data represent the mean ± standard error. The statistical significance between the control sample and the samples treated with lenalidomide, pomalidomide, bortezomib, or carfilzomib with PBS or BsAb5003, respectively, was assessed using the parametric Dunnett’s test (*P < 0.05, **P < 0.01).